Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
HMPL-306 by Hutchison MediPharma for Myelodysplastic Syndrome: Likelihood of Approval
HMPL-306 is under clinical development by Hutchison MediPharma and currently in Phase I for Myelodysplastic Syndrome. According to GlobalData, Phase...
HMPL-306 by Hutchison MediPharma for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia): Likelihood of Approval
HMPL-306 is under clinical development by Hutchison MediPharma and currently in Phase I for Acute Myelocytic Leukemia (AML, Acute Myeloblastic...
Surufatinib by Hutchison MediPharma for Pancreatic Ductal Adenocarcinoma: Likelihood of Approval
Surufatinib is under clinical development by Hutchison MediPharma and currently in Phase III for Pancreatic Ductal Adenocarcinoma. According to GlobalData,...
Surufatinib by Hutchison MediPharma for Metastatic Pancreatic Cancer: Likelihood of Approval
Surufatinib is under clinical development by Hutchison MediPharma and currently in Phase III for Metastatic Pancreatic Cancer. According to GlobalData,...
Surufatinib by Hutchison MediPharma for Ovarian Cancer: Likelihood of Approval
Surufatinib is under clinical development by Hutchison MediPharma and currently in Phase II for Ovarian Cancer. According to GlobalData, Phase...
Surufatinib by Hutchison MediPharma for Soft Tissue Sarcoma: Likelihood of Approval
Surufatinib is under clinical development by Hutchison MediPharma and currently in Phase II for Soft Tissue Sarcoma. According to GlobalData,...
Surufatinib by Hutchison MediPharma for Solid Tumor: Likelihood of Approval
Surufatinib is under clinical development by Hutchison MediPharma and currently in Phase II for Solid Tumor. According to GlobalData, Phase...
Surufatinib by Hutchison MediPharma for Non-Rhabdomyosarcoma: Likelihood of Approval
Surufatinib is under clinical development by Hutchison MediPharma and currently in Phase II for Non-Rhabdomyosarcoma. According to GlobalData, Phase II...
Surufatinib by Hutchison MediPharma for Rhabdomyosarcoma: Likelihood of Approval
Surufatinib is under clinical development by Hutchison MediPharma and currently in Phase II for Rhabdomyosarcoma. According to GlobalData, Phase II...
Surufatinib by Hutchison MediPharma for Ewing Sarcoma: Likelihood of Approval
Surufatinib is under clinical development by Hutchison MediPharma and currently in Phase II for Ewing Sarcoma. According to GlobalData, Phase...
Surufatinib by Hutchison MediPharma for Osteosarcoma: Likelihood of Approval
Surufatinib is under clinical development by Hutchison MediPharma and currently in Phase II for Osteosarcoma. According to GlobalData, Phase II...
Surufatinib by Hutchison MediPharma for Lymphoma: Likelihood of Approval
Surufatinib is under clinical development by Hutchison MediPharma and currently in Phase II for Lymphoma. According to GlobalData, Phase II...
Amdizalisib by Hutchison MediPharma for Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma): Likelihood of Approval
Amdizalisib is under clinical development by Hutchison MediPharma and currently in Phase I for Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated...
Amdizalisib by Hutchison MediPharma for Nodal Marginal Zone B-Cell Lymphoma: Likelihood of Approval
Amdizalisib is under clinical development by Hutchison MediPharma and currently in Phase I for Nodal Marginal Zone B-Cell Lymphoma. According...
Surufatinib by Hutchison MediPharma for Metastatic Biliary Tract Cancer: Likelihood of Approval
Surufatinib is under clinical development by Hutchison MediPharma and currently in Phase II for Metastatic Biliary Tract Cancer. According to...
Surufatinib by Hutchison MediPharma for Fallopian Tube Cancer: Likelihood of Approval
Surufatinib is under clinical development by Hutchison MediPharma and currently in Phase II for Fallopian Tube Cancer. According to GlobalData,...
Surufatinib by Hutchison MediPharma for Peritoneal Cancer: Likelihood of Approval
Surufatinib is under clinical development by Hutchison MediPharma and currently in Phase II for Peritoneal Cancer. According to GlobalData, Phase...
Amdizalisib by Hutchison MediPharma for Splenic Marginal Zone B-Cell Lymphoma: Likelihood of Approval
Amdizalisib is under clinical development by Hutchison MediPharma and currently in Phase I for Splenic Marginal Zone B-Cell Lymphoma. According...
Sovleplenib by Hutchison MediPharma for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma): Likelihood of Approval
Sovleplenib is under clinical development by Hutchison MediPharma and currently in Phase I for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma). According...
Sovleplenib by Hutchison MediPharma for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura): Likelihood of Approval
Sovleplenib is under clinical development by Hutchison MediPharma and currently in Phase I for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)....